Hepatect Cp

Hepatect Cp is a human hepatitis B immunoglobulin supplied as an injectable solution for intravenous administration. It contains purified antibodies against hepatitis B virus; the exact strength is not disclosed. Hepatect Cp is marketed in the European Union and is available by prescription only. The product is classified under ATC code J06BA02 and belongs to the immunoglobulin drug class. It is used for passive immunity against hepatitis B.

Hepatect Cp is indicated for passive immunization against hepatitis B virus in specific clinical situations.

- Post‑exposure prophylaxis for individuals with recent exposure to hepatitis B surface antigen‑positive blood or body fluids. - Prevention of hepatitis B infection in newborns of hepatitis B‑positive mothers when administered within 12 hours of birth. - Supplementation of hepatitis B vaccine in persons with compromised immune response. - Use in patients undergoing liver transplantation to reduce the risk of HBV recurrence.

The safety profile of Hepatect Cp reflects the typical reactions observed with human immunoglobulin preparations.

Common: - Mild fever or chills shortly after infusion. - Headache or fatigue. - Localized injection site redness or swelling. - Nausea or mild gastrointestinal discomfort.

Serious: - Severe allergic reaction or anaphylaxis. - Acute hemolysis. - Renal impairment or acute kidney injury. - Thromboembolic events such as deep vein thrombosis.

When prescribing Hepatect Cp, clinicians should consider several precautionary measures to ensure safe administration.

- Assess patient history for prior hypersensitivity to blood products or immunoglobulins. - Monitor vital signs during and after infusion for signs of reaction. - Adjust infusion rate in patients with cardiovascular disease or compromised circulation. - Use caution in individuals with renal insufficiency or a history of kidney disease. - Avoid use in patients with known IgA deficiency who have anti‑IgA antibodies. - Evaluate hepatitis B serology to confirm need for passive immunization.

Hepatect Cp may interact with other medications or medical conditions, requiring attention to avoid adverse outcomes.

Avoid: - Concurrent administration of other blood‑derived products without appropriate monitoring. - Simultaneous infusion of high‑dose intravenous immunoglobulin preparations.

Use with caution: - Live vaccines administered within 3 months of Hepatect Cp due to potential interference with immune response. - Anticoagulants, as immunoglobulin infusions can affect coagulation parameters. - Diuretics in patients with renal impairment, because of fluid balance considerations. - Cytotoxic chemotherapy agents, which may increase risk of renal toxicity.